Research

	Clinical Trials
	Contin Technology
	Quality

Research in Laboratories, Clinics, and Universities

Research and Development has always been a major component of Purdue Pharma's operations, and we are committed to significant increases in R&D activities, ranging from the development of new molecules through to investigating new applications for existing medications. These opportunities for medical advances are explored in both our own and university-based research laboratories, as well as through clinical studies conducted in hospitals throughout Canada.

Clinical Experience Shared with Physician and Patient

The capability to rapidly transfer information gained from laboratory and clinical research to physicians and other healthcare professionals is as important as the development of new drugs. Our marketing and sales personnel are charged with communicating this valuable information, and are equally concerned with receiving feedback on emerging healthcare requirements.

Insight obtained from our clinical research activities also leads to the development of effective patient education materials, which form an important part of our disease management strategies.

Ongoing Application of Contin Controlled-Release Technologies

In addition to our focus on products for the management of respiratory diseases, pain and other symptoms of cancer, research in our Canadian operation and worldwide affiliated companies is directed at using our Contin controlled-release technology to improve additional drugs for a wide range of conditions.

Contin controlled-release technology provides for closer control over the amount of drug released to the bloodstream, and benefits patients in terms of reducing the number of doses they need to take every day, providing more effective control of their disease (particularly at night), and reducing unwanted side effects.

New Drugs: A Priority

We are significantly enhancing our capability to discover new drugs, particularly in the fields of oncology and central nervous system diseases, including novel products for the treatment of pain.

As knowledge of the underlying mechanism of these diseases advances, our goal is to develop new active substances with more specific activity than currently available drugs.